...
首页> 外文期刊>Molecular pharmaceutics >Poloxamer 407/TPGS Mixed Micelles as Promising Carriers for Cyclosporine Ocular Delivery
【24h】

Poloxamer 407/TPGS Mixed Micelles as Promising Carriers for Cyclosporine Ocular Delivery

机译:泊洛沙姆407 / TPGS混合胶束作为环孢菌素眼递送的有前途的载体

获取原文
获取原文并翻译 | 示例

摘要

Cyclosporine is an immunosuppressant agent approved for the treatment of dry eye disease and used off-label for other ocular pathologies. Its formulation and ocular bioavailability present a real challenge due to the large molecular weight (1.2 kDa), high lipophilicity, and low water solubility. The aim of the work was to develop an aqueous micellar formulation for an efficient cyclosporine delivery to the ocular tissues, using a water-soluble derivative of vitamin E (TPGS: d-α-tocopheryl polyethylene glycol 1000 succinate) and poloxamer 407 (Pluronic ?F127) as excipients. The mixed micelles were characterized in terms of particle size, zeta potential, rheology, and stability upon dilution and freeze-drying. Additionally, the enzymatic-triggered release of vitamin E and vitamin E succinate from TPGS was investigated in vitro in the presence of esterase. Compared to the commercially available ophthalmic formulation, the poloxamer 407:TPGS 1:1 molar ratio micellar formulation significantly improved cyclosporine solubility, which increased proportionally to surfactant concentration reaching 0.4% (w/v) for 20 mM surfactant total concentration. Cyclosporine-loaded mixed micelles efficiently retained the drug once diluted in simulated lachrymal fluid and, in the presence of a 20 mM surfactant concentration, were stable upon freeze-drying. The drug-loaded mixed micelles were applied ex vivo on porcine cornea and compared to Ikervis?. Drug accumulation in the cornea resulted proportional to drug concentration (6.4 ± 1.9, 17.6 ± 5.4, and 26.9 ± 7.4 μg_(drug)/g_(cornea), after 3 h for 1, 2.5, and 4 mg/mL cyclosporine concentration respectively). The formulation containing cyclosporine 4 mg/mL (20 mM surfactant) was also evaluated on the sclera, with a view to targeting the posterior segment. The results demonstrated the capability of mixed micelles to diffuse into the sclera and sustain cyclosporine delivery (28 ± 7, 38 ± 10, 57 ± 9, 145 ± 27 μg/cm~(2) cyclosporine accumulated after 3, 6, 24, and 48 h respectively). Reservoir effect experiments demonstrated that the drug accumulated in the sclera can be slowly released into the underlying tissues. Finally, all the formulations developed in this work successfully passed the HET-CAM assay for the evaluation of ocular irritability.
机译:环孢菌素是一种免疫抑制剂,用于治疗干眼症,用于其他眼部病理学的用途。其配方和眼部生物利用度由于大的分子量(1.2kDa),高亲脂性和低水溶性低而存在真正的挑战。该工作的目的是使用维生素E的水溶性衍生物(TPGS:D-α-生育基聚乙二醇1000琥珀酸盐)和泊洛沙姆407(Pluronic? F127)作为赋形剂。混合胶束以粒度,Zeta电位,流变学和稀释和冷冻干燥时的稳定性表征。另外,在酯酶的存在下,在体外研究了从TPG的维生素E和维生素E琥珀酸的酶促释放。与市售眼科制剂相比,泊洛沙姆407:TPGS 1:1摩尔比胶束制剂显着改善了环孢菌素溶解度,其与表面活性剂浓度成比例增加0.4%(w / v),达到20mM表面活性剂的总浓度。加载环孢菌素加载的混合胶束有效地保留了在模拟的龙轭液中稀释的药物,并且在20mM表面活性剂浓度存在下,在冷冻干燥时稳定。将药物加载的混合胶束施用猪角膜上的离体,并与Ikervis相比?角膜中的药物积累导致药物浓度成比例(6.4±1.9,17.6±5.4,和26.9±7.4μg_(药物)/ g_(角膜),分别为3小时,2.5和4mg / ml环孢菌素浓度) 。还在巩膜上评估含有环孢菌素4mg / ml(20mM表面活性剂)的制剂,以瞄准后段。结果证明了混合胶束的能力扩散到巩膜中并维持3例3,6,24和3,6,24后累积的环孢菌素递送(28±7,38±10,57±9,145±27μg/ cm〜(2)环孢菌素48小时分别)。储层效应实验证明,巩膜中积聚的药物可以缓慢地释放到下面的组织中。最后,在这项工作中开发的所有制剂成功地通过了HET-CAM测定以评估眼睛烦躁。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号